BIOMM has signed an agreement with Nemera to commercialise the company’s Advapen under the trade name Lifepen, for the administration of Glargilin insulin to treat diabetes. Glargilin is a long-acting insulin analogue glargine, which has reportedly shown significantly less risk of hypoglycaemia compared to NPH insulin, in both symptomatic and nocturnal episodes. 1
“We are convinced that the launch of Lifepen will help provide improved health and more quality of life to patients with chronic conditions such as diabetes. Providing a state-of-the-art pen injector with high ergonomics and reliability is extremely important to ensure high patient compliance, which translates into the effectiveness of treatment of diabetes. Due to its dynamic increase, diabetes is already called the epidemic of the 21st century. With the addition of Lifepen we strengthen our existing product portfolio even more,” said Paulo Vidigal, Head of Business Development at BIOMM.
“The collaboration with BIOMM starting from the registration to the filing followed by the approval from ANVISA in just over a year is an incredible achievement for both companies. We are glad that our reusable pen injector Advapen is being launched in the Brazilian market where high unmet medical needs when it comes to diabetes are being addressed,” added Aurélie Oudet-Thebaud, Sales Director International Markets at Nemera.
Advapen is part of Nemera’s PenDURA AD pen platform. The spring-assisted, reusable pen injectors are designed to be ergonomic and customizable, requiring low force of injection. They’re also equipped for automatic delivery of medication, aimed to ensure consistent dosing rate.
References
1. Riddle MC et al Diabetes Care 2003;26:3080-6
